Form 4: Nuvalent Director Emily Conley Reports Stock and Option Awards

Director Emily Conley reported the acquisition of stock and option awards in Nuvalent, Inc.

Summary

• On June 12, 2024, Emily Conley, a director of Nuvalent, Inc., reported transactions involving the company's securities.
• Conley acquired 2,499 shares of Class A Common Stock under restricted stock units (RSUs) at $0.00 per share.
• These RSUs vest on the earlier of June 12, 2025, or the date of Nuvalent's next annual meeting of stockholders, contingent upon continued service to the company.
• Conley also acquired options to purchase 3,789 shares of Class A Common Stock at an exercise price of $80.03.
• These options vest on the earlier of June 12, 2025, or the date of Nuvalent's next annual meeting of stockholders, contingent upon continued service to the company.
• Following these transactions, Conley directly owns 2,507 shares of Class A Common Stock and holds options for 3,789 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports standard compensation practices. The grants align director interests with shareholders, which is generally viewed positively, but it's a routine disclosure.

Positives

• The grant of RSUs and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule tied to continued service incentivizes the director to remain with the company.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can be informative for investors.

Comparison to Industry Standards

• Stock option and RSU grants are common forms of compensation for directors and executives in publicly traded companies, particularly in the biotechnology and pharmaceutical industries.
• Vesting schedules tied to continued service are also standard practice to ensure alignment of interests and retention of key personnel.
• Companies like Relay Therapeutics and Black Diamond Therapeutics also use similar equity-based compensation strategies for their directors.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning the director's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates